<result><Target><Item><Target_ID> 1426</Target_ID>
<Target_Name>Ephrin type-A receptor 4</Target_Name>
<Target_Type>Protein&gt;Receptor</Target_Type>
<Target_Sequence>Q03137</Target_Sequence>
<Synonyms>EC=2.7.10.1
Tyrosine-protein kinase receptor MPK-3
Tyrosine-protein kinase receptor SEK-1</Synonyms>
<Target_Source>Mus musculus (Mouse):10090</Target_Source>
<Target_Structure>1B0X, 2HEL, 2XYU, 2Y6M, 2Y6O</Target_Structure>
<Comments>The EphA4 receptor is expressed in neurons, where it promotes the repulsive guidance of developing axons. EphA4 receptor binds to both type A ephrins and most type B ephrins, but it also forms a hetero receptor complex with fibroblast growth factor receptor (FGFR). </Comments>
</Item><Item><Target_ID> 1427</Target_ID>
<Target_Name>HIV-1 CDC451 gp120</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>None</Target_Source>
<Target_Structure></Target_Structure>
<Comments>Recombinant gp120 CDC451 protein was purchased from Advanced BioScience Labs, MA, USA.</Comments>
</Item><Item><Target_ID> 1428</Target_ID>
<Target_Name>Four- to five-week-old mdx mice heart</Target_Name>
<Target_Type>Organ and tissue</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Mus musculus (Mouse):10090</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1429</Target_ID>
<Target_Name>Four- to five-week-old mdx mice muscle</Target_Name>
<Target_Type>Organ and tissue</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Mus musculus (Mouse):10090</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1430</Target_ID>
<Target_Name>Mixtures of 13 anti-dystrophin monoclonal antibodies</Target_Name>
<Target_Type>Protein&gt;Monoclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Mus musculus (Mouse):10090</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1431</Target_ID>
<Target_Name>IgE of the peanut allergic patient no. 2205</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1432</Target_ID>
<Target_Name>IgE of the peanut allergic patient no. 2208</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1433</Target_ID>
<Target_Name>IgE of the peanut allergic patient no. 2209</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1434</Target_ID>
<Target_Name>IgE of the peanut allergic patient no. 2304</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1435</Target_ID>
<Target_Name>IgE of the peanut allergic patient no. 2305</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1436</Target_ID>
<Target_Name>IgE of animal nr. 19</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Rattus norvegicus (Rat):10116</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1437</Target_ID>
<Target_Name>IgE of animal nr. 49</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Rattus norvegicus (Rat):10116</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1438</Target_ID>
<Target_Name>IgE of animal nr. 52</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Rattus norvegicus (Rat):10116</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1439</Target_ID>
<Target_Name>IgE of animal nr. 53</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Rattus norvegicus (Rat):10116</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1440</Target_ID>
<Target_Name>IgE of animal nr. 54</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Rattus norvegicus (Rat):10116</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1441</Target_ID>
<Target_Name>Interferon-induced, double-stranded RNA-activated protein kinase</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence>P19525</Target_Sequence>
<Synonyms>EC=2.7.11.1
Eukaryotic translation initiation factor 2-alpha kinase 2
eIF-2A protein kinase 2
Interferon-inducible RNA-dependent protein kinase
P1/eIF-2A protein kinase
Protein kinase RNA-activated
PKR
Tyrosine-protein kinase EIF2AK2
EC=2.7.10.2
p68 kinase</Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure>1QU6, 2A19, 2A1A, 3UIU</Target_Structure>
<Comments>Double-stranded RNA-dependent protein kinase (PKR, EC 2.7.11.1) is one of the best-characterized kinases. Structurally , PKR has two functional domains: an Nterminal double-stranded RNA (dsRNA)-binding regulatory domain and a C-terminal kinase catalytic domain. In the catalytic domain (a.a. 251-551) of PKR (named PKRcat), K296 acts as the binding site for ATP, and mutation of K296 (K296R) has a dominant negative effect on the ability of PKR to phosphorylate eIF2α.</Comments>
</Item><Item><Target_ID> 1442</Target_ID>
<Target_Name>Cyclosporin A, CsA</Target_Name>
<Target_Type>Organic molecules or materials</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>None</Target_Source>
<Target_Structure></Target_Structure>
<Comments>CsA is a natural compound showing multiple biological activities, including an immunosuppressive function, anti-chaperone activity, inhibition of transporter activity and antiviral activity against human immunodeficiency virus and HCV.</Comments>
</Item><Item><Target_ID> 1443</Target_ID>
<Target_Name>Serum of dogs with VL</Target_Name>
<Target_Type>Miscellaneous</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Canis familiaris (Dog) (Canis lupus familiaris):9615</Target_Source>
<Target_Structure></Target_Structure>
<Comments>The blood serum samples from animals with CVL were selected on the basis of two serological tests (IFAT [IFATLVC Bio-Manguinhos kit] and ELISA [EIE-LVC Bio-Manguinhos kit], both from Bio-Manguinhos, Fiocruz, Brazil) for Leishmania spp. Animals with an IFAT titer of &gt; 1:40 and an ELISA value over the cutoff were considered to be seropositive.</Comments>
</Item><Item><Target_ID> 1444</Target_ID>
<Target_Name>Anti-BDE47 monoclonal antibody 1H2</Target_Name>
<Target_Type>Protein&gt;Monoclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Mus musculus (Mouse):10090</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1445</Target_ID>
<Target_Name>Mab 1H2-BDE47 immunocomplex</Target_Name>
<Target_Type>Organic molecules or materials</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>None</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1446</Target_ID>
<Target_Name>BDE47-polyclonal antibody immunocomplex</Target_Name>
<Target_Type>Organic molecules or materials</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>None</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1447</Target_ID>
<Target_Name>Proprotein convertase subtilisin/kexin type 9, PCSK9</Target_Name>
<Target_Type>Protein&gt;Enzyme</Target_Type>
<Target_Sequence>Q8NBP7</Target_Sequence>
<Synonyms>EC=3.4.21.-
Neural apoptosis-regulated convertase 1
NARC-1
Proprotein convertase 9
PC9
Subtilisin/kexin-like protease PC9</Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure>2P4E, 2PMW, 2QTW, 2W2M, 2W2N, 2W2O, 2W2P, 2W2Q, 2XTJ, 3BPS, 3GCW, 3GCX, 3H42, 3M0C, 3P5B, 3P5C, 3SQO, 4K8R, 4NMX</Target_Structure>
<Comments>PCSK9 is an ideal antibody target because it circulates in blood and has only modest binding affinity to cell surface LDL receptor and its main interaction site is an exposed 500-Å2 slightly convex region that is readily available for antibody binding.</Comments>
</Item><Item><Target_ID> 1448</Target_ID>
<Target_Name>Bovine insulin-Like growth factor-binding protein 2, bIGFbp-2</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence>P13384</Target_Sequence>
<Synonyms>IBP-2
IGF-binding protein 2
IGFBP-2</Synonyms>
<Target_Source>Bos taurus (Bovine):9913</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1449</Target_ID>
<Target_Name>Death-associated protein kinase 1</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence>P53355</Target_Sequence>
<Synonyms>DAP kinase 1
EC=2.7.11.1</Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure>1IG1, 1JKK, 1JKL, 1JKS, 1JKT, 1P4F, 1WVW, 1WVX, 1WVY, 1YR5, 2W4J, 2W4K, 2X0G, 2XUU, 2XZS, 2Y0A, 2Y4P, 2Y4V, 2YAK, 3DFC, 3DGK, 3EH9, 3EHA, 3F5G, 3F5U, 3GU4, 3GU5, 3GU6, 3GU7, 3GU8, 3GUB, 3ZXT, 4B4L, 4PF4</Target_Structure>
<Comments>At the biochemical level DAPK-1 is composed of several functional domains, including its kinase domain, ankyrin repeat domain, calmodulin binding domain, and death domain.</Comments>
</Item><Item><Target_ID> 1450</Target_ID>
<Target_Name>Globotriaosylceramide, Gb3</Target_Name>
<Target_Type>Organic molecules or materials</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>None</Target_Source>
<Target_Structure></Target_Structure>
<Comments>Globotriaosylceramide (Gb3) was purchased from Matreya LLC (Pleasant Gap, PA, USA).</Comments>
</Item></Target></result>